NCT04057339

Brief Summary

In a randomized controlled trial, the investigators intend to measure the health impact of TRE in patients with metabolic syndrome (with three or more of the following criteria: increased waist circumference, abnormal cholesterol levels, elevated blood pressure, or elevated blood sugar), who habitually eat for more than 14 hours every day. Patients will be randomly assigned to a control group of behavioral nutrition counseling (standard of care) or the intervention group of behavioral nutrition counseling with the addition of adopting a 8-10 hour eating window for 12 weeks (TRE).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
122

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 2, 2019

Completed
6 days until next milestone

Study Start

First participant enrolled

April 8, 2019

Completed
4 months until next milestone

First Posted

Study publicly available on registry

August 15, 2019

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

April 6, 2023

Status Verified

April 1, 2023

Enrollment Period

4.2 years

First QC Date

April 2, 2019

Last Update Submit

April 3, 2023

Conditions

Keywords

Time Restricted EatingCircadian RhythmGlucose HomeostasisMitochondrial FunctionFasting

Outcome Measures

Primary Outcomes (2)

  • Change in glucose levels assessed via HbA1c

    HbA1c (%)

    Baseline and 14 weeks

  • Change in glycemic parameters

    Glycemic parameters assessed via fasting glucose (mg/dL), HOMA-IR, Insulin (mIU/L), and continuous glucose monitors (CGM).

    Baseline and 14 weeks

Secondary Outcomes (6)

  • Change in LDL particle number

    Baseline and 14 weeks

  • Change in LDL cholesterol

    Baseline and 14 weeks

  • Change in HDL cholesterol

    Baseline and 14 weeks

  • Change in Triglycerides

    Baseline and 14 weeks

  • Change in body composition by DXA

    Baseline and 14 weeks

  • +1 more secondary outcomes

Other Outcomes (1)

  • Change in mitochondrial structure and gene expression in skeletal muscle

    Baseline and 14 weeks

Study Arms (2)

SOC (Standard of Care)

PLACEBO COMPARATOR

Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.

Behavioral: Standard of Care

TRE + SOC

EXPERIMENTAL

Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.

Behavioral: Time Restricted Eating + Standard of Care

Interventions

Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.

Also known as: Time Restricted Eating
TRE + SOC

Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.

SOC (Standard of Care)

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-75 years
  • ≥ BMI ≥ 25 AND
  • Metabolic syndrome, as defined as presence of 3 or more of the following criteria:
  • Elevated fasting plasma glucose ≥ 100 mg/dL and/or HbA1c ≥ 5.7% \< 7.1% Elevated waist circumference: In Asians: ≥ 90 cm in men, ≥ 80 cm in women, all other races: ≥ 102 cm in men, ≥ 88 cm in women Fasting plasma triglycerides ≥ 150 mg/dL, or on drug treatment for elevated triglycerides Reduced High-density lipoprotein (HDL)-cholesterol \< 40 mg/dL in males or \< 50 mg/dL in females, or drug treatment for reduced HDL-cholesterol Elevated blood pressure, Systolic blood pressure ≥ 135 mm Hg and/or diastolic blood pressure ≥ 85 mm Hg or drug treatment for hypertension
  • Own a smartphone (Apple iOS or Android OS)
  • Baseline eating period ≥ 12 hour window
  • If patients are on cardiovascular medications (HMG CoA reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive, anti-diabetes drugs), no dose adjustments will be allowed during the study period.

You may not qualify if:

  • Taking insulin within the last 6 months.
  • Manifest diabetes, defined as HbA1c \> 7.0% given a 0.3% margin of error in lab readings, or diagnosis of diabetes.
  • Known inflammatory and/or rheumatologic disease.
  • Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse.
  • Pregnant or breast-feeding women.
  • Shift workers with variable (e.g. nocturnal) hours.
  • Caregivers for dependent requiring frequent nocturnal care/sleep interruptions.
  • Planned travel to a time zone with greater than a 3-hour difference during study period.
  • History of major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)).
  • History of adrenal disease.
  • History of malignancy undergoing active treatment, except non-melanoma skin cancer.
  • Known history of type I diabetes.
  • History of eating disorder(s).
  • History of cirrhosis.
  • History of stage 4 or 5 chronic kidney disease or requiring dialysis.
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Altman Clinical and Translational Research Institute

La Jolla, California, 92093, United States

Location

Related Publications (2)

  • Manoogian ENC, Wilkinson MJ, O'Neal M, Laing K, Nguyen J, Van D, Rosander A, Pazargadi A, Gutierrez NR, Fleischer JG, Golshan S, Panda S, Taub PR. Time-Restricted Eating in Adults With Metabolic Syndrome : A Randomized Controlled Trial. Ann Intern Med. 2024 Nov;177(11):1462-1470. doi: 10.7326/M24-0859. Epub 2024 Oct 1.

  • Taub PR, Panda S. Time for better time-restricted eating trials to lessen the burden of metabolic diseases. Cell Rep Med. 2022 Jun 21;3(6):100665. doi: 10.1016/j.xcrm.2022.100665.

MeSH Terms

Conditions

Metabolic SyndromeGlucose IntoleranceIntermittent FastingFasting

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesHyperglycemiaFeeding BehaviorBehavior

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Pam Taub, MD

    Associate Professor of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine

Study Record Dates

First Submitted

April 2, 2019

First Posted

August 15, 2019

Study Start

April 8, 2019

Primary Completion

June 1, 2023

Study Completion

June 1, 2023

Last Updated

April 6, 2023

Record last verified: 2023-04

Locations